Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Spindle Cell Sarcoma
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related cancers:
‹
Sarcoma (668
)
Soft Tissue Sarcoma (443
)
Leiomyosarcoma (54
)
Osteosarcoma (54
)
Ewing Sarcoma (45
)
Fibrosarcoma (34
)
Rhabdomyosarcoma (34
)
Liposarcoma (25
)
Uterine Corpus Leiomyosarcoma (23
)
Kaposi Sarcoma (13
)
Neurofibrosarcoma (13
)
Sarcoma (668
)
Soft Tissue Sarcoma (443
)
Leiomyosarcoma (54
)
Osteosarcoma (54
)
Ewing Sarcoma (45
)
Fibrosarcoma (34
)
Rhabdomyosarcoma (34
)
Liposarcoma (25
)
Uterine Corpus Leiomyosarcoma (23
)
Kaposi Sarcoma (13
)
Neurofibrosarcoma (13
)
›
Associations
(100)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Leiomyosarcoma
No biomarker
Leiomyosarcoma
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
trabectedin
Sensitive: A1 - Approval
trabectedin
Sensitive
:
A1
No biomarker
Fibrosarcoma
No biomarker
Fibrosarcoma
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
imatinib
Sensitive: A1 - Approval
imatinib
Sensitive
:
A1
No biomarker
Uterine Corpus Leiomyosarcoma
No biomarker
Uterine Corpus Leiomyosarcoma
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
pazopanib
Sensitive: A2 - Guideline
pazopanib
Sensitive
:
A2
No biomarker
Fibrosarcoma
No biomarker
Fibrosarcoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
ER positive
Uterine Corpus Leiomyosarcoma
ER positive
Uterine Corpus Leiomyosarcoma
Aromatase inhibitor
Sensitive: A2 - Guideline
Aromatase inhibitor
Sensitive
:
A2
Aromatase inhibitor
Sensitive: A2 - Guideline
Aromatase inhibitor
Sensitive
:
A2
PGR positive
Uterine Corpus Leiomyosarcoma
PGR positive
Uterine Corpus Leiomyosarcoma
Aromatase inhibitor
Sensitive: A2 - Guideline
Aromatase inhibitor
Sensitive
:
A2
Aromatase inhibitor
Sensitive: A2 - Guideline
Aromatase inhibitor
Sensitive
:
A2
No biomarker
Leiomyosarcoma
No biomarker
Leiomyosarcoma
eribulin mesylate
Sensitive: A2 - Guideline
eribulin mesylate
Sensitive
:
A2
eribulin mesylate
Sensitive: A2 - Guideline
eribulin mesylate
Sensitive
:
A2
PGR positive
Uterine Corpus Leiomyosarcoma
PGR positive
Uterine Corpus Leiomyosarcoma
medroxyprogesterone
Sensitive: A2 - Guideline
medroxyprogesterone
Sensitive
:
A2
medroxyprogesterone
Sensitive: A2 - Guideline
medroxyprogesterone
Sensitive
:
A2
ER positive
Uterine Corpus Leiomyosarcoma
ER positive
Uterine Corpus Leiomyosarcoma
medroxyprogesterone
Sensitive: A2 - Guideline
medroxyprogesterone
Sensitive
:
A2
medroxyprogesterone
Sensitive: A2 - Guideline
medroxyprogesterone
Sensitive
:
A2
PGR positive
Uterine Corpus Leiomyosarcoma
PGR positive
Uterine Corpus Leiomyosarcoma
megestrol
Sensitive: A2 - Guideline
megestrol
Sensitive
:
A2
megestrol
Sensitive: A2 - Guideline
megestrol
Sensitive
:
A2
ER positive
Uterine Corpus Leiomyosarcoma
ER positive
Uterine Corpus Leiomyosarcoma
megestrol
Sensitive: A2 - Guideline
megestrol
Sensitive
:
A2
megestrol
Sensitive: A2 - Guideline
megestrol
Sensitive
:
A2
No biomarker
Leiomyosarcoma
No biomarker
Leiomyosarcoma
doxorubicin hydrochloride + dacarbazine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + dacarbazine
Sensitive
:
A2
doxorubicin hydrochloride + dacarbazine
Sensitive: A2 - Guideline
doxorubicin hydrochloride + dacarbazine
Sensitive
:
A2
No biomarker
Leiomyosarcoma
No biomarker
Leiomyosarcoma
BMIi-1
Sensitive: B - Late Trials
BMIi-1
Sensitive
:
B
BMIi-1
Sensitive: B - Late Trials
BMIi-1
Sensitive
:
B
NTRK1 fusion
Neurofibrosarcoma
NTRK1 fusion
Neurofibrosarcoma
entrectinib
Sensitive: C1 - Off-label
entrectinib
Sensitive
:
C1
entrectinib
Sensitive: C1 - Off-label
entrectinib
Sensitive
:
C1
NTRK3 fusion
Neurofibrosarcoma
NTRK3 fusion
Neurofibrosarcoma
entrectinib
Sensitive: C1 - Off-label
entrectinib
Sensitive
:
C1
entrectinib
Sensitive: C1 - Off-label
entrectinib
Sensitive
:
C1
NTRK1 fusion
Spindle Cell Sarcoma
NTRK1 fusion
Spindle Cell Sarcoma
entrectinib
Sensitive: C1 - Off-label
entrectinib
Sensitive
:
C1
entrectinib
Sensitive: C1 - Off-label
entrectinib
Sensitive
:
C1
NTRK3 fusion
Spindle Cell Sarcoma
NTRK3 fusion
Spindle Cell Sarcoma
entrectinib
Sensitive: C1 - Off-label
entrectinib
Sensitive
:
C1
entrectinib
Sensitive: C1 - Off-label
entrectinib
Sensitive
:
C1
BRAF V600E
Neurofibrosarcoma
BRAF V600E
Neurofibrosarcoma
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
NTRK3 fusion
Fibrosarcoma
NTRK3 fusion
Fibrosarcoma
larotrectinib
Sensitive: C1 - Off-label
larotrectinib
Sensitive
:
C1
larotrectinib
Sensitive: C1 - Off-label
larotrectinib
Sensitive
:
C1
NTRK2 fusion
Fibrosarcoma
NTRK2 fusion
Fibrosarcoma
larotrectinib
Sensitive: C1 - Off-label
larotrectinib
Sensitive
:
C1
larotrectinib
Sensitive: C1 - Off-label
larotrectinib
Sensitive
:
C1
NTRK1 fusion
Fibrosarcoma
NTRK1 fusion
Fibrosarcoma
larotrectinib
Sensitive: C1 - Off-label
larotrectinib
Sensitive
:
C1
larotrectinib
Sensitive: C1 - Off-label
larotrectinib
Sensitive
:
C1
BRAF V600E
Synovial Sarcoma
BRAF V600E
Synovial Sarcoma
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
vemurafenib
Sensitive: C1 - Off-label
vemurafenib
Sensitive
:
C1
CTAG1B expression
Synovial Sarcoma
CTAG1B expression
Synovial Sarcoma
TBI-1301
Sensitive: C2 – Inclusion Criteria
TBI-1301
Sensitive
:
C2
TBI-1301
Sensitive: C2 – Inclusion Criteria
TBI-1301
Sensitive
:
C2
KRAS G12V
Spindle Cell Sarcoma
KRAS G12V
Spindle Cell Sarcoma
BAL3833
Sensitive: C3 – Early Trials
BAL3833
Sensitive
:
C3
BAL3833
Sensitive: C3 – Early Trials
BAL3833
Sensitive
:
C3
AKT1 E17K
Uterine Corpus Leiomyosarcoma
AKT1 E17K
Uterine Corpus Leiomyosarcoma
capivasertib
Sensitive: C3 – Early Trials
capivasertib
Sensitive
:
C3
capivasertib
Sensitive: C3 – Early Trials
capivasertib
Sensitive
:
C3
SMARCB1 negative
Spindle Cell Sarcoma
SMARCB1 negative
Spindle Cell Sarcoma
tazemetostat
Sensitive: C3 – Early Trials
tazemetostat
Sensitive
:
C3
tazemetostat
Sensitive: C3 – Early Trials
tazemetostat
Sensitive
:
C3
Chr amplification(4)(q22.1)
Leiomyosarcoma
Chr amplification(4)(q22.1)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
Chr del(3)(q14.2)
Leiomyosarcoma
Chr del(3)(q14.2)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
Chr del(11)(q25)
Leiomyosarcoma
Chr del(11)(q25)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
Chr del(2)(q14.1)
Leiomyosarcoma
Chr del(2)(q14.1)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
Chr del(2)(p12)
Leiomyosarcoma
Chr del(2)(p12)
Leiomyosarcoma
eribulin mesylate
Sensitive: C3 – Early Trials
eribulin mesylate
Sensitive
:
C3
eribulin mesylate
Sensitive: C3 – Early Trials
eribulin mesylate
Sensitive
:
C3
Chr del(1)(q44)
Leiomyosarcoma
Chr del(1)(q44)
Leiomyosarcoma
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
eribulin mesylate
Resistant: C3 – Early Trials
eribulin mesylate
Resistant
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login